Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GFER | P55789 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | TERT | O14746 | 1/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1308333 | 0.82 | ADRA2C (0.60) | L3MBTL1GAASMN1; SMN2GFERMAPT | |
| Catechol SCHEMBL28483503 | 0.78 | SMN1; SMN2 (0.54) | L3MBTL1CYP2D6GAASMN1; SMN2ALDH1A1 | |
| Catechol SCHEMBL9390287 | 0.78 | SMN1; SMN2 (0.54) | L3MBTL1CYP2D6GAASMN1; SMN2ALDH1A1 | |
| Phenol SCHEMBL1308949 | 0.76 | ADRA2C (0.53) | L3MBTL1GAASMN1; SMN2GFERKMT2A | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL29261751 | 0.75 | CYP2D6 (0.60) | L3MBTL1CYP2D6GAASMN1; SMN2ALDH1A1 | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL15994943 | 0.75 | CYP2D6 (0.60) | L3MBTL1CYP2D6GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL5470285 | 0.75 | GAA (0.60) | L3MBTL1GAASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL7220234 | 0.74 | L3MBTL1 (0.60) | L3MBTL1HTR6GAAALDH1A1GFER | |
| N-Methylpiperidine SCHEMBL2149763 | 0.74 | CYP2D6 (0.59) | L3MBTL1CYP2D6GAASMN1; SMN2ALDH1A1 | |
| Orthocresol SCHEMBL28343544 | 0.74 | LMNA (0.49) | L3MBTL1CYP2D6GAASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6545037-B2 | Thromboxane A2 (TXA2) receptor and 5HT2 serotonergic receptor antagonists; 3-(6-(((4-chlorophenyl)sulphonyl)amino)-3-((2-(4-methyl-1 -piperazinyl)phenoxy)methyl)-5,6, 7,8-tetrahydro-1-naphthyl)propanoic acid for example | LES LABORATOIRES SERVIER (FR) | 2003-04-08 | — | — | US | disclosed |
| US-6469011-B2 | NITROGEN OXIDE YIELDING AND THROMBOXANE A2 (TXA2) AND SEROTONIN (5HT2) RECEPTOR ANTAGONIST; TREATMENT OF ATHEROTHROMBOTIC CARDIOVASCULAR DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-10-22 | — | — | US | disclosed |
| US-20020137742-A1 | Benzenesulfonamide compounds | LAVIELLE GILBERT (FR) | 2002-09-26 | — | — | US | disclosed |
| EP-1118610-B1 | Benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2002-08-21 | — | — | EP | disclosed |
| US-20010009915-A1 | New benzenesulfonamide compounds | LES LABORATOIRES SERVIER (FR) | 2001-07-26 | — | — | US | disclosed |
| EP-1118610-A1 | Benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009915-A1 | New benzenesulfonamide compounds | CNR1, CNR2, HTR1A | L3MBTL1 3898/4885HTR6 36/4885CYP2D6 230/4885 |
| US-20020137742-A1 | Benzenesulfonamide compounds | CNR1, CNR2, HTR1A | L3MBTL1 3710/4885HTR6 40/4885CYP2D6 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.